CAL-101, an oral inhibitor of PI3Kδ, is being evaluated for its safety, pharmacokinetics, pharmacodynamics, and clinical activity in patients with relapsed or refractory hematologic malignancies, including CLL, B-cell NHL, AML, and MM. The study's completion in August 2012 positions Gilead Sciences to leverage potential market opportunities in the oncology space, particularly in indications with high unmet medical needs. The competitive landscape includes other PI3K inhibitors, such as idelalisib, which may impact market entry strategies and pricing. Diligence should focus on the drug's safety profile and efficacy data to assess its potential for regulatory approval and market uptake.